Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Extended Market Index ETF Vanguard (VXF)

Extended Market Index ETF Vanguard (VXF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fund Basics

See More
  • Fund Family Vanguard Group
  • Assets Under Management 24,876,884,800
  • Shares Outstanding, K 116,760
  • 60-Month Beta 1.18
  • Price/Earnings ttm 21.80
  • Annual Dividend & Yield 2.30 (1.08%)
  • Most Recent Dividend 0.576 on 09/24/25
  • Management Fee 0.05%
  • INDUSTRY GROUPING:

    ETFs - Mid Cap

Options Overview Details

View History
  • Implied Volatility 20.29% (-0.98%)
  • Historical Volatility 19.40%
  • IV Percentile 18%
  • IV Rank 11.51%
  • IV High 44.28% on 04/08/25
  • IV Low 17.17% on 01/23/25
  • Expected Move (DTE 12) 1.53 (0.72%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 5
  • Volume Avg (30-Day) 7
  • Put/Call OI Ratio 0.44
  • Today's Open Interest 341
  • Open Int (30-Day) 344
  • Expected Range 211.53 to 214.59

Price Performance

See More
Period Period Low Period High Performance
1-Month
195.90 +8.76%
on 11/21/25
214.32 -0.59%
on 12/05/25
+3.76 (+1.80%)
since 11/05/25
3-Month
195.90 +8.76%
on 11/21/25
216.00 -1.36%
on 10/27/25
+5.27 (+2.54%)
since 09/05/25
52-Week
146.68 +45.25%
on 04/07/25
216.00 -1.36%
on 10/27/25
+8.19 (+4.00%)
since 12/05/24

Most Recent Stories

More News
Ensysce Biosciences Stock Rises On Positive Data From Opioid Overdose Protection Study: Retail’s Thrilled

The company stated that a 100 mg dosage of PF614-MPAR delivers oxycodone to treat severe pain and provides overdose protection when a greater-than-prescribed dose is consumed.

VXF : 213.06 (-0.08%)
ENSC : 1.6400 (+0.61%)
Cara Therapeutics Stock Jumps 10% After Announcing 1-for-3 Reverse Stock Split: Retail Sentiment Soars

On Tuesday evening, every three issued and outstanding shares of CARA’s common stock will automatically be combined into one, effectively reducing the number of issued and outstanding shares of the company's...

CARA : 15.96 (-4.14%)
VXF : 213.06 (-0.08%)
VTI : 337.56 (+0.14%)
Bath & Body Works Stock Upgraded By Piper Sandler On Strong Brand Interest, Attractive Share Price: Retail Investors Very Interested

The brand was a popular choice for fragrances among teenagers in the U.S., according to a Piper Sandler survey.

IJR : 121.63 (-0.17%)
VXF : 213.06 (-0.08%)
VTI : 337.56 (+0.14%)
BBWI : 18.83 (-0.95%)
WeightWatchers Reportedly Considers Bankruptcy Amid Business Struggles, Debt Woes: Retail Traders On Edge

hares of the company, which is struggling with a declining business and high debt levels, fell over 60% after the report.

WW : 24.11 (-6.98%)
VXF : 213.06 (-0.08%)
VTI : 337.56 (+0.14%)
Phio Pharmaceuticals Stock Soars On Clearance To Escalate Dose In Skin Cancer Treatment Trial: Retail’s Thrilled

CEO Robert Bitterman said the company is optimistic that the clinical trial will continue to demonstrate that PH-762 may present a viable non-surgical alternative to existing modes of therapy for skin...

VXF : 213.06 (-0.08%)
PHIO : 1.3100 (-2.96%)
Immunic Stock Draws Investor Attention On $5.1M Registered Direct Offering: Retail’s On Wait-And-Watch Mode

Immunic intends to use the net proceeds from the proposed offering to fund its clinical trials and operations and for other general corporate purposes.

IMUX : 0.6646 (-3.44%)
VXF : 213.06 (-0.08%)
VTI : 337.56 (+0.14%)
Cosmos Health Announces Launch Of Food Supplement Brand In Albania: Retail Sentiment Improves

The company said that the launch is in partnership with Tirana-based pharmaceutical company Pharma Cell, which will serve as the distributor in the country.

VXF : 213.06 (-0.08%)
COSM : 0.4616 (-6.94%)
iBio Stock Plummets Despite Positive Data On Weight-Loss Treatment Antibody: Retail Stays Bearish

However, the company said that the study does not prove statistical significance and only involves a single administration of the antibody.

VXF : 213.06 (-0.08%)
DFAT : 59.74 (+0.03%)
IBIO : 1.2000 (-6.25%)
Aptevo Stock Rises On $2.1M Registered Direct Offering, Warrant Sale: Retail Sentiment Touches Year-High

The company said that net proceeds from the offering will be used for the continued clinical development of product candidates, as working capital, and for other general corporate purposes.

VXF : 213.06 (-0.08%)
APVO : 1.3500 (-2.88%)
Rivian Reports 36% Drop in Q1 Deliveries, But Retail Continues To Be Positive

Truist Securities noted that the numbers aligned with the company’s prior commentary and street estimates, although the shares could see headwinds today from Tesla reporting Q1 deliveries below estimates...

VXF : 213.06 (-0.08%)
RIVN : 17.95 (-0.61%)
VTI : 337.56 (+0.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Fund Summary

The Vanguard Extended Market ETF seeks to track the performance of the SP Completion Index.

See More

Key Turning Points

3rd Resistance Point 215.63
2nd Resistance Point 214.98
1st Resistance Point 214.02
Last Price 213.06
1st Support Level 212.40
2nd Support Level 211.75
3rd Support Level 210.79

See More

52-Week High 216.00
Last Price 213.06
Fibonacci 61.8% 189.52
Fibonacci 50% 181.34
Fibonacci 38.2% 173.16
52-Week Low 146.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar